BUSINESS COMBINATION - Purchase Price Allocation (Details) - USD ($) $ in Thousands		3 Months Ended
	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Business Acquisition [Line Items]
Cash paid upon consummation		$ 0	$ 33,430
Asklepion Pharmaceuticals, LLC
Business Acquisition [Line Items]
Common stock shares issued (in shares)	661,279
Cash paid upon consummation	$ 33,430
Present value of contingent consideration and service fees	42,010		42,010
Fair Value of 661,279 shares issued to Asklepion	15,844
Total Purchase Price	91,284		91,284
Fair Value of Assets Acquired and Liabilities Assumed
Acquired product rights-Cholbam (Intangible Asset)	83,200		83,200
Pediatric Priority Review Voucher	96,250		96,250
Inventory	777		777
Deferred tax liability	(39,880)		(39,880)
Total Allocation of Purchase Price	140,347		$ 140,347
Bargain Purchase Gain	(49,063)
Total Purchase Price	$ 91,284